| 1 |
29717260 | A modified gene trap approach for improved high-throughput cancer drug discovery. | 2018 Aug |
1 |
| 2 |
26479578 | In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study. | 2016 Oct |
1 |
| 3 |
27157787 | Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters. | 2016 May 9 |
1 |
| 4 |
26458439 | [State-of-the-art management of CML in 2015 and future prospects]. | 2015 Oct |
1 |
| 5 |
24258348 | Ever-advancing chronic myeloid leukemia treatment. | 2014 Feb |
1 |
| 6 |
23380277 | A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas. | 2013 May |
1 |
| 7 |
23747655 | Bafetinib inhibits functional responses of human eosinophils in vitro. | 2013 Sep 5 |
1 |
| 8 |
23787070 | Bcr-Abl tyrosine kinase inhibitors- current status. | 2013 Jun 20 |
2 |
| 9 |
24130846 | A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL. | 2013 |
1 |
| 10 |
19890374 | A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. | 2010 Jan |
3 |
| 11 |
20310049 | Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. | 2010 Jun 1 |
1 |
| 12 |
20597967 | Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor? | 2010 Oct |
1 |
| 13 |
21124949 | A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib. | 2010 Nov 18 |
1 |
| 14 |
21154127 | Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia. | 2010 Dec |
5 |
| 15 |
18191450 | Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. | 2008 Jun |
1 |
| 16 |
18338755 | Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification. | 2008 Jun 1 |
2 |
| 17 |
18759691 | Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. | 2008 Sep |
1 |
| 18 |
17301549 | [Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia]. | 2007 Feb |
2 |
| 19 |
19662183 | NS-187 (INNO-406), a Bcr-Abl/Lyn dual tyrosine kinase inhibitor. | 2007 Nov 14 |
2 |
| 20 |
16332440 | Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. | 2006 Mar 1 |
1 |
| 21 |
16546254 | In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. | 2006 Nov |
4 |
| 22 |
18221045 | Second generation Abl kinase inhibitors and novel compounds to eliminate the Bcr-Abl/T315I clone. | 2006 Nov |
1 |
| 23 |
16105974 | NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. | 2005 Dec 1 |
2 |